ユタにおける濾胞性リンパ腫の臨床試験
ユタ内の拠点で、濾胞性リンパ腫に関する13件の研究が参加者を募集しています。
ユタ内の都市
公式研究テキスト（英語）
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Huntsman Cancer Institute/University of Utah, Salt Lake City
被験者募集中第3相
12歳以上 · 全性別 · 2026/10/02更新 · NCT07215910A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Intermountain Healthcare, Salt Lake City
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Huntsman Cancer Institute, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT05765812A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Salt Lake City
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/21更新 · NCT06549595A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Huntsman Cancer Institute - Oncology Division, Salt Lake City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06091254Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Huntsman Cancer Institute/University of Utah, Salt Lake City
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Huntsman Cancer Insititute, University of Utah, Salt Lake City
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- University of Utah, Salt Lake City
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06651177A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Huntsman Cancer Institute, University of Utah, Salt Lake City
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT04775745A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Utah, Salt Lake City
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/14更新 · NCT05643742SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。